Insights into incretin-based therapies for treatment of diabetic dyslipidemia

被引：29
作者：
Stemmer, Kerstin [1 ,2 ,3 ,4 ]
Finan, Brian [5 ]
DiMarchi, Richard D. [6 ]
Tschoep, Matthias H. [1 ,2 ,3 ,7 ]
Mueller, Timo D. [1 ,2 ,3 ,8 ]
机构：
[1] Helmholtz Zentrum Munchen, Inst Diabet & Obes, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[2] Helmholtz Zentrum Munchen, Helmholtz Diabet Ctr, Neuherberg, Germany
[3] Helmholtz Zentrum Munchen, German Ctr Diabet Res DZD, Neuherberg, Germany
[4] Univ Konstanz, Dept Biol, Constance, Germany
[5] Novo Nordisk Res Ctr Indianapolis, Indianapolis, IN 46241 USA
[6] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA
[7] Tech Univ Munich, Dept Med, Div Metab Dis, Munich, Germany
[8] Karls Univ Hosp & Clin, Eberhard Inst Expt & Clin Pharmacol & Pharmacogen, Dept Pharmacol Expt Therapy & Toxicol, D-72076 Tubingen, Germany
来源：
ADVANCED DRUG DELIVERY REVIEWS | 2020年 / 159卷
基金：
欧洲研究理事会;
关键词：
Incretins; Lipoproteins; Dyslipidemia; Diabetes; Obesity; GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT INSULINOTROPIC POLYPEPTIDE; LIPOPROTEIN-LIPASE ACTIVITY; LOW-DENSITY-LIPOPROTEIN; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; BROWN ADIPOSE-TISSUE; HIGH-FAT; RECEPTOR AGONIST;
D O I：
10.1016/j.addr.2020.05.008
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia. (C) 2020 Published by Elsevier B.V.
引用
收藏
页码：34 / 53
页数：20
相关论文
共 266 条
[51]   The Cardiovascular Biology of Glucagon-like Peptide-1 [J].
Drucker, Daniel J. .
CELL METABOLISM, 2016, 24 (01) :15-30
[52]   Induction of intestinal epithelial proliferation by glucagon-like peptide 2 [J].
Drucker, DJ ;
Ehrlich, P ;
Asa, SL ;
Brubaker, PL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7911-7916
[53]   STIMULATION OF INSULIN-SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN [J].
DUPRE, J ;
ROSS, SA ;
WATSON, D ;
BROWN, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1973, 37 (05) :826-828
[54]   INHIBITION OF ACTIONS OF GLUCAGON IN ADIPOCYTES BY GASTRIC INHIBITORY POLYPEPTIDE [J].
DUPRE, J ;
MCDONALD, TJ ;
ROSS, SA ;
RUBINSTEIN, D .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1976, 25 (11) :1197-1199
[55]  
EATON RP, 1973, J LIPID RES, V14, P312
[56]   EFFECT OF EXOGENOUS OR ENDOGENOUS GASTRIC-INHIBITORY POLYPEPTIDE (GIP) ON PLASMA TRIGLYCERIDE RESPONSES IN RATS [J].
EBERT, R ;
NAUCK, M ;
CREUTZFELDT, W .
HORMONE AND METABOLIC RESEARCH, 1991, 23 (11) :517-521
[57]   GASTRIC-INHIBITORY POLYPEPTIDE ENHANCED LIPOPROTEIN-LIPASE ACTIVITY IN CULTURED PREADIPOCYTES [J].
ECKEL, RH ;
FUJIMOTO, WY ;
BRUNZELL, JD .
DIABETES, 1979, 28 (12) :1141-1142
[58]   GLUCAGON-LIKE PEPTIDE-1 CELLS IN THE GASTROINTESTINAL-TRACT AND PANCREAS OF RAT, PIG AND MAN [J].
EISSELE, R ;
GOKE, R ;
WILLEMER, S ;
HARTHUS, HP ;
VERMEER, H ;
ARNOLD, R ;
GOKE, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (04) :283-291
[59]   Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study [J].
Eliasson, B. ;
Moeller-Goede, D. ;
Eeg-Olofsson, K. ;
Wilson, C. ;
Cederholm, J. ;
Fleck, P. ;
Diamant, M. ;
Taskinen, M. -R. ;
Smith, U. .
DIABETOLOGIA, 2012, 55 (04) :915-925
[60]   GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE SECRETION IN RESPONSE TO NUTRIENT INGESTION IN MAN - ACUTE POSTPRANDIAL AND 24-H SECRETION PATTERNS [J].
ELLIOTT, RM ;
MORGAN, LM ;
TREDGER, JA ;
DEACON, S ;
WRIGHT, J ;
MARKS, V .
JOURNAL OF ENDOCRINOLOGY, 1993, 138 (01) :159-166
12345678910